Mutational landscape of primary, metastatic, and recurrent ovarian cancer reveals c-MYC gains as potential target for BET inhibitors
Charles Li, Elena Bonazzoli, Stefania Bellone, Jungmin Choi, Weilai Dong, Gulden Menderes, Gary Altwerger, Chanhee Han, Aranzazu Manzano, Anna Bianchi, Francesca Pettinella, Paola Manara, Salvatore Lopez, Ghanshyam Yadav, Francesco Riccio, Luca Zammataro, Burak Zeybek, Yang Yang-Hartwich, Natalia Buza, Pei HuiSerena Wong, Antonella Ravaggi, Eliana Bignotti, Chiara Romani, Paola Todeschini, Laura Zanotti, Valentina Zizioli, Franco Odicino, Sergio Pecorelli, Laura Ardighieri, Dan Arin Silasi, Babak Litkouhi, Elena Ratner, Masoud Azodi, Gloria S. Huang, Peter E. Schwartz, Richard P. Lifton, Joseph Schlessinger, Alessandro D. Santin
Research output: Contribution to journal › Article › peer-review
Dive into the research topics of 'Mutational landscape of primary, metastatic, and recurrent ovarian cancer reveals c-MYC gains as potential target for BET inhibitors'. Together they form a unique fingerprint.